All News

US.knee_.jpg

Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care

Jiha Lee, MD

Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and Psoriatic Arthritis.” This is the first update in a decade since the 2012 ACR guidance on the reasonable use of MSUS in rheumatology clinical practice.

Read Article
EULAR19.abstract.jpg (keep)

ACR 2024 - Featured Industry Presentations

Jack Cush, MD

ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Read Article
biosimilars2.jpg

Biosimilar Slow Growth in USA

Jack Cush, MD

A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.

Read Article
RheumNow Podcast square

Dr. Quotes (11.8.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.

Read Article
COVID.virus_.corona.jpg (keep)

COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders

Jack Cush, MD

A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.

Read Article
Location of research matters Ab#0772 Global recruiting patterns impact PBO in PsA PBO results improve w time - 0.9%/year More globalization of trials w time Gross nation index (GNI) neg ass w ACR20 - inclusion of less affluent controls affects higher PBO response @RheumNow #ACR24

Eric Dein ericdeinmd ( View Tweet)

TNFi cycling vs. switching to IL-17Ai? Dr @AlexisOgdie et al from CorEvitas registry: PsA & axSpA cohort - switchers (TNFi to IL17i) had greater improvements in cDAPSA & BASDAI vs. cyclers (2nd TNF) Not stat significant but offers alternative Tx options @RheumNow #ACR24 abs585 https://t.co/8m347BRM75

Links:

sheila RHEUMarampa ( View Tweet)
Dr. Catherine Bakewell @CatherineB27 shares the preliminary ACR guidelines on ultrasound imaging in psoriatic arthritis covering 4 domains, detailed PICOs covering the early phase, diagnosis, assessment covering the domains of PsA @RheumNow #ACR24 https://t.co/DoHE1rsSGf

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Dactylitis management in PsA: Acute: pain and swelling Chronic: painless swelling Broad ddx No role for LEF or SSZ #ReviewCourse #ACR24 @RheumNow https://t.co/KZXv1UvhXn

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Great summary of treatment choices in PsA: 1. Identify domain involved 2. Identify comorbidities/pt preferences 3. Still unmet needs for ttx in inflammatory eye disease #ACR24 @rheumnow https://t.co/1WMnkDYvip

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients! Don’t forget the 5Ms! 🧠Mind (cog/mood) 💊Medication (PIM) 🏃‍♀️Mobility 👉Multi-complexity 💪🏻Matters most (pt priority) @RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX

Links:

Patricia Harkins DrTrishHarkins ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Dr. John Cush RheumNow ( View Tweet)

Pain in PsA = predictor of disability and QoL TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated biomarkers vs PBO @RheumNow #ACR24 Abstract #2366 https://t.co/DAgmdmmTE0

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Summary of treatments in psoriatic arthritis #PsA @RheumNow #ACR24 https://t.co/EybzRCPLtA

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Dr. Quotes (11.8.2024) Dr. Jack Cush reviews the news and journal reports from this past week from https://t.co/V10S4oWdi3. https://t.co/NEXFg3Mp5G https://t.co/tUkGSgm6O7

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/vwNFU501di
Dr. John Cush RheumNow ( View Tweet)
Scleroderma registry enrolled SSc pts w/o ILD. Incident ILD occurred in 199/969 (21%) pts over median 2.4yrs. Late onset SSc-ILD (>7yr from Raynauds) occurs 32% less. These pts were more White, w/ arthritis & RNA-polymerase III Abs, but have similar ILD Progression (vs… https://t.co/zdL4OPEPhi https://t.co/wl9XmsCHIE
Dr. John Cush RheumNow ( View Tweet)
Taiwan claims data study of 135 230 patients who received antineoplastic medications, found that immune checkpoint inhibitors use was associated with a 2-fold increased risk of developing psoriasis (HR 2.43). https://t.co/m5eGT56W12 https://t.co/h5FjQpHOpF

Links:

Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 176 CASPAR+ PsA patients correlated Dz activity (cDAPSA) w/ SAA, IL-8, IP10 (IFNg/CXCL10), M-CSF, SCGF-β, SDF-1α) (AUC 0.802- 0.835). The panel was significantly better than CRP (AUC = 0.727, p = 0.022). https://t.co/AZq81S6NH0 https://t.co/5eI241gLVj

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×